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Summary medium may produce false positive results (11). In this report, we
describe two modifications of the original Bethesda assay which result 
Antibodies against factor VIII coagulant activity can appear in in markedly increased specificity and allowed us to diagnose and moni- 
haemophiliacs who are treated with factor VIII preparations but also tor the presence of factor VIII :C inhibitors, 
spontaneously in non-haemophiliacs. The Bethesda assay is the most 
commonly used method to detect these antibodies, but it lacks speci-
ficity especially in the lower range resulting in unreliable data.
Two modifications are proposed and tested to resolve the imper­
fections:
1. Buffering the normal plasma used in the assay- and control mixture 
with 0.1 M imidazole to pH 7.4.
p
2. Replacing the imidazole buffer in the control mixture by immuno-
depleted factor VIII deficient plasma.
These modifications allow better discrimination between positive 
and negative samples and improve reliability.
Introduction
*
The development of factor VUI-inhibitors may complicate substitu­
tion treatment in haemophiliacs. Consequently, these patients are in 
danger of uncontrolled bleeding and need long-term treatment with 
expensive factor VIII preparations to induce immunotolerance.
Early reports concerning the incidence of inhibitors were controver­
sial (1 ), but recent prospective studies confirmed their presence in the 
blood between 5% and 20% of haemophiliacs (2-8). Moreover, inhibi­
tors were also detected in healthy individuals (9).
The reasons for the wide variation in results are manifold and in­
clude the type of concentrate used, the severity of haemophilia, ex- Original Bethesda Assay
Materials and Methods
Plasma Preparation
Nine volumes of blood were drawn into one volume of 0.13 M sodium 
citrate using Vacutainers (Becton-Dickinson, New Yersey, USA). Plasma was 
prepared by centrifugation for 15 inin at 4300 X g and 4° C, then stored at 
-70°  C until required.
Normal pooled plasma (N-pool) was prepared by mixing plasma from at 
least 50 healthy blood donors aged 18-65 years selected to represent all blood 
groups and sexes equally.
Buffering was achieved by adding solid imidazole (Merck, Darmstadt, 
Germany) to yield a concentration of 0.1 M then adjusting the pH by slowly 
adding 1 N HC1 while constantly stirring at 4° C.
Factor VIII: C Assay
Factor VIII¡Coagulant activity (FVIII:C activity) was measured in a one 
stage APTT-based clotting assay (12) using PTT(a)-reagent (Stago, Asniere, 
France), Immu nodepleted factor VIII deficient plasma (Organon Teknika, 
Durham, USA) and N-pool as a 100% reference.
Clotting times were recorded with a KC-10 coagulometer (Amelung, 
Lemgo, Germany).
posure time as well as ethnic origin, family history and age at the start 
of substitution therapy. However, both over- and underestimation 
might originate from the use of the Bethesda assay used to detect in­
hibitors. There is no agreed cut-off value for the Bethesda Units 
(BU/ml) to discriminate between inhibitor-positive and negative pa­
tients which range from zero to 0.8 BU/ml (2-10) which indicates that 
the assay lacked specificity especially at the lower range of activity, 
We recently drew attention to this anomaly and reported that in­
sufficient buffering and variable protein concentration in the assay
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Anti-FVIII:C activity was measured with the Bethesda assay according to 
Kasper (13).
N-pool was mixed with either an equal volume of patient plasma (test mix­
ture) or with 0.1 M imidazole buffer pH 1A  (control mixture). After 2 h of in­
cubation at 37° C, the relative percentage FVIII: C activity of the test mixture 
compared to the control mixture (residual FV III: C activity) was determined. 
The FVIII :C activity in the test mixture was corrected for intrinsic residual 
F V III: C activity (e. g. at mild or sub-haemophilia).
One Bethesda Unit (BU) was defined as that amount o f inhibitor that 
resulted in 50% residual FVIII: C activity.
The inhibitor activity was read in BU/ml from a semilogarilhmic plot repre­
senting the correlation between residual FVIII :C activity (logarithmic) and in­
hibitor activity (linear) (13). When the residual FV III:C  activity of undiluted 
sample was below 25%, retesting was performed by diluting with 0.1 M imi­
dazole buffer pH 7.4 until a residual FVIII :C activity of 25% to 75% was 
obtained.
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Table I pH values and remaining FVIII: C activities in test- and control mixtures of the original and modified Bethesda assay
Assay mixtures pH
before
incubation
. pH 
after 2 h •
incubation
Remaining 
FVIII : C
activity {%)
Non-buffered N-pool and haemophilic 
plasma (inhibitor free) 1:1
7.7 ±0.1 8.3 ±0.1 68 ± 6
Non-buffered N-pool and 0.1 M 
imidazole buffer pH 7.4 1:1
7.6 ± 0.1 7.8 ±0.1 83 ± 6
0.1 M imidazole buffered N-pool pH 7.4 and 
haemophilic plasma 1:1
7.4 ±0.1 7.4 ± 0.1 95 ± 5
0.1 M imidazole buffered N-pool and 
immunodepleted factor VIII deficient plasma 1 :1
7.4 ±0.1 7.4 ±0.1 97 ± 4
0.1 M imidazole buffered N-pool and 
0.9% saline 1:1
7.4 ±0.1 7.4 ±0.1 83 ± 8
Ail data are the means of 5 determinations ± the standard deviation.
Modified Bethesda Assay
Test plasma as well as immunodepleted factor VIII deficient control plasma 
(pool of at least 20 individuals, Organon Teknika, Durham, USA) were mixed 
with equal volumes of 0.1 M imidazole buffered N-pool pH 7.4 and incubated 
for 2 h at 37° C. The FVIII :C activity was measured in both mixtures and 
corrected for the intrinsic activity. The inhibitor activity was quantified as 
described for the original Bethesda assay. If necessary, plasma samples were 
diluted before testing with immunodepleted factor VIII deficient plasma.
In addition, samples with inhibitor activity of more than 2 BU/ml were also 
assayed by empirically determining the plasma concentration which gives 50% 
inhibition. Therefore, a number of dilutions were tested and the residual
concentration that gave 50% residual FVIII: C activity was estimated by extra­
polation and the reciprocal value of it equals the inhibitor activity in BU/ml.
FVIII:C activity of at least 4 assays within the range of 25% to 75% were 
plotted versus the plasma dilution semilogarithmically or arithmetically. The
7 .2 0  7 .4 0  7 .6 0  7 .8 0  8 .0 0  8 .2 0  8 .4 0
actual pH in assay mixture
Fig. I pH dependent FVIII :C inactivation. Remaining FVIII: C activity is 
measured in mixtures o f 0.1 M imidazole buffered N-pool and either haemo-
philic plasma (------ ), immunodepleted factor VIII deficient plasma (— ) or
saline 0.9% (— ) after 2 h incubation at 37° C. Data are the mean of 5 assays ± 
the standard deviation. The plotted pH represents the actual pH measured after 
incubation and differs from that of the preset value of the buffered N-pool 
because of the intrinsic buffering capacity of the other constituents in the 
mixtures
pH bistability in Assay Mixtures andpH-dependenl FVIII: C Inactivation
pH values and FVIII: C activities were measured in test and control mix­
tures of the original and the modified Bethesda assay before and after 2 h of 
incubation at 37° C.
pH related FVIII: C inactivation was studied by measuring both pH and 
FVIII :C activity before and after, 2 h  of incubation at 37° C in mixtures of 
N-pool containing 0.1 M imidazole buffered at pH 7.0,'7.4, 7.7, 8.0,8.3 and
8.6, and either citrated congenital FVIII deficient plasma (inhibitor free), 
immunodepleted FVIII deficient plasma (Organon Teknika, Durham, USA) or 
saline (0.9% NaCl).
The remaining FVIII;C activity was defined as the activity obtained after 
incubation compared to the preincubation value.
All pH measurements were carried out with a PHM-92-meter (Radiometer, 
Copenhagen, Denmark).
Patients
Samples of plasma were obtained from 4 groups of patients: 32 haemophil­
iacs without history of inhibitor: 10 with less than 1 percent FVIII; C activity 
(group la) and 22 with activity between I and 20% (group lb), 5 patients with a 
history of factor VIII inhibitor but free of medication and symptoms of inhibi­
tor at the time of sampling (group 11), 6 patients who were being treated for an 
inhibitor at the time of sampling and still had evidence of inhibitor-activity such 
as bleeding complications and decreased recovery after factor VIII substitution 
(group III) and 8 patients with high levels of inhibitor activity in the initial 
stage of treatment with immunosuppressives (group IV).
Results
p H  Changes and FVIII: C Inactivation
The pH of the mixture of non-buffered N-pool and inhibitor-free 
haemophilic plasma (fesf mixture in the original Bethesda assay) in­
creased to about 8.3 during incubation whereas the pH of the original 
control mixture of N-pool with 0.1 M imidazole-buffer pH 7.4 only 
slightly increased to about 7.8 (Table 1). In addition, a lower amount of 
FVIII : C activity was remaining in the test mixture compared to the 
control mixture (p <0.05). Buffering the N-pool with 0.1 M imidazole 
stabilized the pH in the mixtures with factor VIII deficient plasma, both 
congenital and immunodepleted, and 0.9% saline at the initial value of 
pH 7.4. The FVIII : C inactivation was only 3-5% in the buffered plas­
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Table 2 Anti-FVIII: C activity in patient samples with the original and modified Bethesda assay
Category Type of patient F V III : C 
activity 
in plasma
(%)
No.
of
patients
Inhibitor 
activity 
original assay 
(BU/ml)
Inhibitor
activity
modified assay 
(BU/ml)
la Severe haemophiliacs 
no history of inhibitor
<1 10 0.5-0.9 0.0
lb Mild/sub-haemophiliacs 
no history of inhibitor
1-20 22 0.5—0.9 0.0
II Haemophiliacs 
history of inhibitor 
free of symptoms and 
medication
2-8 5 0.1-0,7 0.0
III Haemophiliacs under 
treatment for inhibitor
<1-3 6 0,5-1.9 0.6-1.7
IV Patients with high level 
of inhibitor in initial 
stage of treatment
<1 7 13-315 10-320
Table 3 Inhibitor assays with the modified Bethesda method in samples with high inhibitor activities
Patient no.
(type of inhibitor)
A B
Dilution
factor
Residual 
FV III; C activity
Calculated inhibitor activity Empirically estimated 
(BU/ml) inhibitor activity (BU/ml)
KD 250 66 150 180
100 24 205
2(1) 200 76 80 85
40 20 116
3(1) 120 74 54 60
40 26 78
4 (D ' 200 75 84 105
75 33 120 9
5(1) 40 84 10 17
10 29 18
6(H) 400 71 200 220
50 29 90
7 (II) 800 76 320 320
100 38 140
i
Column A; Plasma samples were assayed in two different dilutions and inhibitor activities were calculated from the correlation graph and multiplied with the 
dilution factor.
Column B: Plasma samples were assayed in at least 4 different dilutions and the activity was estimated by finding the dilution giving 50% inhibition.
ma mixtures rising to approximately 17% in mixtures with saline. This 
relation between pH and FVIII: C inactivation was further investigated 
in mixtures of buffered N-pool at various pH levels and factor VIII 
deficient plasma or saline (Fig, 1). FVIII; C inactivation increased with 
increasing pH but was only marginal at physiological pH. FVIII: C 
inactivation in mixtures with half the protein concentration was higher 
at all pH levels compared to mixtures of N-pool and deficient plasma.
Patients
4
No inhibitor activity was detected with the modified method in 
the samples obtained from the 32 haemophiliacs of groups la and lb 
whereas with the original assay inhibitor activities ranging from
0.5 to 0.9 BU/ml were found (Table 2).
Plasma from the patients in group II showed no activity in the modi­
fied assay whereas with the original assay the activity ranged from
0.1 to 0.7 BU/ml. With both methods increased inhibitor activities 
were detected in all samples from patients in group III, but all except 
one sample showed lower activities (0.2-0.4 BU) with the modified 
method. All samples from patients in group IV showed high activities 
with both methods, However, the calculated inhibitor activity in the 
latter varied with the degree of plasma dilution (Table 3, column A). In 
plasma of patients with type I inhibitor (samples 1-5) the activity 
increased with decreasing dilution whereas the empirically deter­
mined data were in between (Table 3, column B). In contrast, plasma of 
patients of type II inhibitor (6 » 7) showed maximal activity at the 
highest dilution and the empirically determined inhibitor activities 
were even higher.
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Residual FVIII: C activity
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Type I
1
0 . 0 0 0 0 .005 0.010 0.015 0.020
plasma dilution
Fig. 2 Correlation between logarithm of residual F V III: C activity and plasma concentration of a sample with high inhibitor activity type I and type II
Typical curves representing the relation between plasma dilution 
and residual FVIII: C activity in type I and type II patients are shown 
in Fig. 2. None of the samples exhibited a linear correlation between 
concentration and the logarithm of the residual FVIII: C activity.
Discussion
The Bethesda assay is the most widely used method for detection of 
FVIII: C inhibitors. FVIII: C inactivation in both a test mixture (normal 
plasma/patient plasma) and a control mixture (normal plasma/0.1 M degree of dilution. This appears to be due to the aberrant kinetics of fac- 
imidazole buffer pH 7.4) is measured and expressed in inhibitor ac- tor VIII and its inhibitor which is not linearly correlated but is complex 
tivity. as was implied but not specifically noted by Kasper (13), reported by
hibitor activity that was absent at the time of sampling gave identical 
results.
Samples from patients that were receiving immunosuppressive 
medication and who still had clinical evidence that an inhibitor was 
present, showed elevated activities with both methods but the activities 
with the modified method were lower than with the original method.
These data indicate that the specificity of the modified method was 
improved while the sensitivity remained unchanged.
The specificity for detection of high inhibitor activities was similar 
with both methods but the calculated activities were dependent on the
We observed a significant increase in pH and FVIII: C inactivation Biggs (14) and confirmed by our findings. Data above the hypothetical
in mixtures of N-pool and inhibitor-free factor VIII deficient plasma, linear curve between 50% and 100% residual FVIII: C activity of each
In experiments with imidazole-buffered N-pool (pH ranging from individual sample will result in an underestimation of inhibitor activity
7.2 to 8.3) we showed that FVIII: C inactivation increases with pH and whereas data below the curve will result in the converse which explains
that reduced protein concentration leads to further inactivation of 
FVIII : C activity. These phenomena may be the source of falsely posi­
tive inhibitor activities in patient samples when assayed with the origi­
nal Bethesda assay. We therefore introduced two substitutions in order 
to circumvent these imperfections.
Firstly, the N-pool plasma used in test and control mixture was 
buffered with 0.1 M imidazole to stabilize.the pH at 7.4. Secondly, the 
imidazole buffer in the control mixture was replaced by immuno- 
depleted factor VIII deficient plasma to attain comparable protein 
concentrations in both mixtures. As a result, FVIII : C inactivation was 
virtually identical in both control and test mixtures being marginal in 
both.
Plasma-samples of 32 haemophiliacs which were free of inhibitor 
activity yielded values of O.OBU/ml with the modified method, 
whereas activities between 0.5 and 0.9 BU/ml were obtained with the 
original method. Plasma-samples from patients with a history,of in-
the anomalies shown in Table 3, Quantification of high inhibitor ac­
tivities will be erroneous unless a concentration-independent assay is 
devised.
If there is a need for more uniform quantification, e. g. follow-up of 
treatment, it may be more relevant to estimate empirically the plasma 
dilution that gives 50% inhibition.
In conclusion, we present two modifications of the original Bethes­
da assay which improve the specificity and reliability and suggest a 
method for the optimal quantification of high inhibitor activities.
We suggest to define this method the “Nijmegen assay” for detection 
and quantification of FVIII : C inhibitors.
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